Analysts remained upbeat on the group’s prospects, following its fourth-quarter (Q4) results briefing on Monday.
PETALING JAYA: Pharmaniaga Bhd
is poised for continued improvement as it rides on vaccine sales in the near term while leveraging a potential renewal of its concession agreement for longer-term growth.
Analysts remained upbeat on the group’s prospects, following its fourth-quarter (Q4) results briefing on Monday.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
